Targeted Mitochondrial Therapies

Stealth BioTherapeutics’ research and development team is working to build a strong and focused pipeline in mitochondrial targeted therapies. Our scientific focus is on the mitochondria and on the ways in which mitochondrial therapy can positively impact the lives of patients. Our lead investigational compound, elamipretide, is formulated for systemic (subcutaneous injection and intravenous infusion) and topical ophthalmic delivery.

Elamipretide is uniquely able to target the inner mitochondrial membrane, restoring electron transport to improve cellular energy production and reduce oxidative stress.8 This clinical candidate is being developed for both rare and common diseases, representing a novel therapeutic approach with the potential to treat a wide variety of unmet patient needs.

Stealth BioTherapeutics continues to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.

Mitochondrial Carrier Technology Program

The goal of Stealth BioTherapeutic’s Mitochondrial Carrier Technology (MCT) platform is to utilize the unique ability of our proprietary compounds to deliver biologically-active cargo to mitochondria.